The U.S. is increasingly dependent on imports for drugs. One reason: a tax avoidance scheme that pits U.S. manufacturing up against Europe. What can be done about this problem?
U.S. Senator Bill Cassidy (R-LA) has released a discussion draft of a sweeping, ambitious bill titled the “Americas Act”. The bill states its aim to
The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
By Charles Benoit, CPA Trade Counsel In December, the U.S.-China Commission, a group created by Congress to advise on managing the bilateral relationship, formally recommended
One of India’s pharmaceutical labs has run afoul of the FDA many times this year. The U.S. is dependent on foreign labs like Aurobindo for its drug supply. Can the government help change that?
As 2022 winds down, one thing remains clear, globalization is losing support among policy makers, and even among influencers like Paul Krugman.
The State Department awarded subsidiaries of The Gap in India and Intel in Costa Rica for actions taken by those companies there. Here’s why the parent companies never would have qualified.
Treasury says the dollar is overvalued, but has no plans to fix it. Wall Street will remain the deciding factor in the dollar’s fate. Meanwhile, foreign central banks take action.
China’s Zero Covid protests should persuade Washington, businesses, and consumers that dependence on China for manufacturing American goods will dull the shine off iconic American brands. Political risks are rising.
